Orchestra BioMed Holdings, Inc. (OBIO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David P. Hochman | Founder, Chairman of the Board of Directors & CEO | 916.48k | -- | 1975 |
| Mr. Darren R. Sherman | Founder, President, COO & Director | 914.48k | -- | 1971 |
| Mr. Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 562.41k | -- | 1971 |
| Mr. William Reed Little | Executive Vice President of Corporate Development & Strategy | -- | -- | 1971 |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM & CTO of Bioelectronic Therapies | -- | -- | 1959 |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer | -- | -- | -- |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation | -- | -- | 1956 |
| Mr. Bob Laughner | Senior Vice President of Regulatory & Quality | -- | -- | -- |
| Mr. Juan Lorenzo | Senior Vice President of Product Development | -- | -- | -- |
| Mr. Mark Pomeranz | GM & Executive VP of Interventional Therapies | -- | -- | 1962 |
Orchestra BioMed Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 70
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Corporate Governance
Upcoming Events
May 12, 2025 at 8:28 PM UTC
Orchestra BioMed Holdings, Inc. Earnings Date